Evidence map›Paper›PMID 41323436›Full record

ArticlemicroPublication biology2025

Chronopharmacology of AAV gene therapy in mice.

Patrick Erickson, Alexandra Burr, Biju Parekkadan

Abstract read
In one paragraph

Article in microPublication biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Patrick EricksonChemical and Biochemical Engineering, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States.
Alexandra BurrBiomedical Engineering, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States.
Biju ParekkadanBiomedical Engineering, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The promise of adeno-associated virus (AAV) vectors for gene therapy is held back by the cost and toxicity of the large doses required. This experiment explored the chronopharmacology of AAVs in mice by studying how circadian phase at the time of injection impacted AAV efficacy and revealed that intraperitoneal doses of AAVs injected during the resting phase (ZT6, 12:00PM) produced greater transgene expression over several weeks than equivalent doses injected during the waking phase (ZT18, 12:00AM). This insight could lead to future work that improves safety and reduces costs of AAV gene therapy and other nanoparticle therapies.

Identifiers

PMID41323436
PMCPMC12658587

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.